![]() |
![]() |
Legal status
Patent not validated
(51) | INT.CL. | A61K 38/17 | |
A61P 25/02 | |||
A61K 38/00 |
(11) | Number of the document | 2061485 |
(13) | Kind of document | T |
(96) | European patent application number | 07804199.3 |
Date of filing the European patent application | 2007-09-10 | |
(97) | Date of publication of the European application | 2009-05-27 |
(45) | Date of publication and mention of the grant of the patent | 2012-08-22 |
(46) | Date of publication of the claims translation |
(86) | Number | PCT/GB2007/003401 |
Date | 2007-09-10 |
(87) | Number | WO 2008/029167 |
Date | 2008-03-13 |
(30) | Number | Date | Country code |
0617734 | 2006-09-08 | GB |
(72) |
HAMER, John, GB
|
(73) |
Varleigh Immuno Pharmaceuticals (VIP) Ltd,
Landmark Fiduciaire (Suisse) SA 6 Place des Eaux-Vives Case Postale 3461, 1211 Geneva 3,
CH
|
(54) | EV576 peptides for use in the treatment of Guillain Barré syndrome |
EV576 peptides for use in the treatment of Guillain Barré syndrome |